Cancer News

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer (11/29/2019)

The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many cancers including NSCLC. These drugs are designed to help the immune system recognize and fight cancer. Opdivo belongs to a class of medicines... Continue Reading

Alunbrig Continues to Demonstrate Superiority in the First – Line After Two Years of Follow-Up for ALK + NSCLC (11/27/2019)

Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor demonstrate that with 25 months of follow up Alunbrig continues to demonstrate overall and intracranial effectiveness compared... Continue Reading

E-Cigarette Smoke Causes Lung Cancer in Mice (10/08/2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with nicotine for 54 weeks developed lung adenocarcinomas. None of the 20 mice from the study... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC (10/04/2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA clinical trial presented at the ESMO Congress in Oct 2019. (1,2) the median overall survival with osimertinib was 38.6 months compared to 31.8... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC (09/27/2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the study, Thomas E. Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina, and colleagues sought to determine whether adding bevacizumab to standard... Continue Reading

FDA Approves Keytruda for Small Cell Lung Cancer (06/18/2019)

The  Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Efficacy was investigated in 83 patients with SCLC who had disease progression on or after two or more... Continue Reading

Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC (11/08/2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori (crizotinib) and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on Alcensa (alectinib) or Zykadia …

Continue reading "Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC"

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC (11/05/2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib …

Continue reading "FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC"

November Is National Lung Cancer Awareness Month (10/23/2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the advancement of precision cancer medicines and immunotherapy. Lung cancer however remains the second …

Continue reading "November Is National Lung Cancer Awareness Month"

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone (10/15/2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable mutations in non-small cell lung cancer (NSCLC), researchers from the Abramson Cancer Center of …

Continue reading "Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone"